Miami (AFP) - Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, helped obese people lose an average of 18 pounds (eight kilograms), a yearlong study said.Most patients were able to keep the weight off for the duration of the 56-week study on the drug marketed as Saxenda by Novo Nordisk, according to the findings published in the New England Journal of Medicine.The randomized, controlled trial was conducted at 191 sites in 27 countries in Europe, North America, South America, Asia, Africa and Australia.Patients in the study were 18 and older and each had a body mass index of 30 or higher.BMI is calculated by weight in kilograms divided by the square of the height in meters.